ZA200809527B - Treatment for depressive disorders - Google Patents

Treatment for depressive disorders

Info

Publication number
ZA200809527B
ZA200809527B ZA200809527A ZA200809527A ZA200809527B ZA 200809527 B ZA200809527 B ZA 200809527B ZA 200809527 A ZA200809527 A ZA 200809527A ZA 200809527 A ZA200809527 A ZA 200809527A ZA 200809527 B ZA200809527 B ZA 200809527B
Authority
ZA
South Africa
Prior art keywords
treatment
depressive disorders
depressive
disorders
Prior art date
Application number
ZA200809527A
Other languages
English (en)
Inventor
Birznieks Gunther
Phadke Deepak
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of ZA200809527B publication Critical patent/ZA200809527B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
ZA200809527A 2006-05-22 2008-11-07 Treatment for depressive disorders ZA200809527B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74784306P 2006-05-22 2006-05-22

Publications (1)

Publication Number Publication Date
ZA200809527B true ZA200809527B (en) 2009-11-25

Family

ID=38724081

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809527A ZA200809527B (en) 2006-05-22 2008-11-07 Treatment for depressive disorders

Country Status (12)

Country Link
US (1) US20090209638A1 (es)
EP (1) EP2029564A4 (es)
JP (1) JP2009538334A (es)
KR (1) KR20090024140A (es)
CN (1) CN101448805B (es)
AU (1) AU2007253704A1 (es)
BR (1) BRPI0712014A2 (es)
CA (1) CA2652421A1 (es)
MX (1) MX2008014840A (es)
RU (1) RU2445973C2 (es)
WO (1) WO2007137247A2 (es)
ZA (1) ZA200809527B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
EP2266975A1 (en) * 2009-06-15 2010-12-29 Ferrer Internacional, S.A. 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds
US9789093B2 (en) * 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
WO2013063289A1 (en) * 2011-10-25 2013-05-02 Lycus Llc Pharmaceutical compositions for treating pain
HUE034876T2 (hu) 2012-01-26 2018-03-28 Vanda Pharmaceuticals Inc Cirkadián ritmussal kapcsolatos rendellenességek kezelése
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
WO2013176220A1 (ja) * 2012-05-25 2013-11-28 国立大学法人京都大学 概日リズム調整
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
UA107653U (uk) * 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
CN105142630A (zh) 2012-12-18 2015-12-09 万达制药公司 昼夜节律紊乱的治疗
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
MA43815A (fr) * 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
WO2018205935A1 (zh) 2017-05-09 2018-11-15 浙江大学 治疗抑郁症的方法和药物组合物
WO2019028245A1 (en) 2017-08-02 2019-02-07 Vanda Pharmaceuticals Inc. USE OF TASIMELTÉON FOR THE TREATMENT OF AFFECTIVE DISORDERS
CN115006375A (zh) * 2022-06-24 2022-09-06 华中科技大学 艾司氯胺酮用于制备治疗社交障碍药物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912096A (en) * 1989-06-26 1990-03-27 E. R. Squibb & Sons, Inc. Method for preventing or treating depression employing an ace inhibitor
IL129999A (en) 1996-12-10 2004-06-20 Bristol Myers Squibb Co Melatonergic agents which are benzodioxole, benzopuran, dihydrobenzopuran and benzodioxane
US6562858B2 (en) * 1999-05-17 2003-05-13 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating depression
WO2001002392A1 (en) * 1999-06-30 2001-01-11 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
US6835728B2 (en) * 2000-01-19 2004-12-28 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

Also Published As

Publication number Publication date
AU2007253704A1 (en) 2007-11-29
MX2008014840A (es) 2008-12-05
WO2007137247A3 (en) 2008-01-24
KR20090024140A (ko) 2009-03-06
US20090209638A1 (en) 2009-08-20
AU2007253704A2 (en) 2009-01-08
EP2029564A4 (en) 2010-01-13
JP2009538334A (ja) 2009-11-05
CN101448805B (zh) 2012-12-12
RU2008150621A (ru) 2010-06-27
CN101448805A (zh) 2009-06-03
CA2652421A1 (en) 2007-11-29
RU2445973C2 (ru) 2012-03-27
WO2007137247A2 (en) 2007-11-29
EP2029564A2 (en) 2009-03-04
BRPI0712014A2 (pt) 2011-12-27

Similar Documents

Publication Publication Date Title
ZA200809528B (en) Treatment for depressive disorders
ZA200809527B (en) Treatment for depressive disorders
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
ZA200900734B (en) Combination treatment for metabolic disorders
GB0602178D0 (en) Therapeutic treatment
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
GB0624874D0 (en) Treatment
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
GB0606604D0 (en) Treatment apparatus
EP2010187A4 (en) CONNECTIONS FOR DISEASES AND FUNCTIONAL DISORDERS
IL194739A0 (en) Dihydrothienopyrimidine for treating inflammatory disorders
EP2057953A4 (en) TREATMENT TOOL FOR AN ENDOSCOPE
IL193747A0 (en) New therapeutic combinations for the treatment of depression
GB0600692D0 (en) Well treatment
PL1993589T3 (pl) Sposoby leczenia chorób neurologicznych
EP2230910A4 (en) PRE-SURGICAL TREATMENT
GB0608655D0 (en) Therapeutic Treatment
GB0711342D0 (en) Well treatment
EP2106253A4 (en) TREATMENT OF ACOUPHEN
GB0610909D0 (en) Therapeutic treatment
GB0525540D0 (en) New treatment
GB0607952D0 (en) Novel treatment
GB0702537D0 (en) Treatment for excessive adiposity
GB0716784D0 (en) Well treatment
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych